Unknown

Dataset Information

0

Treatment interruption and associated factors among patients registered on drug-resistant tuberculosis treatment in Amhara regional state, Ethiopia: 2010-2017.


ABSTRACT: BACKGROUND:Drug-Resistant Tuberculosis (DR-TB) is a rising threat of the TB control program caused mainly by treatment interruption in Ethiopia. The success of the current treatment regimen for DR-TB is poor partly due to a high treatment interruption rate. Thus, this study assessed treatment interruption and associated factors among DR-TB patients. METHODS:An institution-based cross-sectional study was conducted among 550 DR-TB patients who have initiated treatment from September 2010 to December 2017. Data were entered using Epi Data version 4.200 and exported to STATA version 14 for analysis. A bi-variable logistic regression model was first fitted, and variables having a p-value < 0.2 in the bi-variable analysis were entered into the multivariable logistic regression model. Crude and Adjusted Odds Ratios (COR and AOR) with 95% confidence interval (CI) were used to determine the strength of association between the treatment interruption and independent variables. Variables with p-value <0.05 in the multi-variable model were considered as statistically significant predictors of treatment interruption. RESULTS:In this study, the prevalence of treatment interruption among patients registered on DR-TB treatment was 14.55% (95% CI: 11.83, 17.76). Of the interrupters, the treatment interruption during the intensive and continuation phase of treatment was reported as 45% and 71.25%, respectively. Similarly, about 15% of patients had treatment interruption both during the intensive and continuation phase of treatment. The average duration of treatment interruption was 12 (±2.03 SD) and 6 (±1.2 SD) days during the intensive and continuation phase of treatment, respectively. Patients who had no treatment supporter [AOR = 1.45; 95% CI: 1.23-3.66] and developed adverse drug events [AOR = 1.60; 95% CI: 1.22-2.85] were statistically significant predictors of treatment interruption. CONCLUSIONS:Treatment interruption was low in the study setting. The presence of treatment supporter and absence of drug side effects was significantly associated with decreased occurrence of treatment interruption. Thus, patient linkage to treatment supporter and excellent pharmacovigilance are highly recommended in the study setting.

SUBMITTER: Merid MW 

PROVIDER: S-EPMC7556470 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Treatment interruption and associated factors among patients registered on drug-resistant tuberculosis treatment in Amhara regional state, Ethiopia: 2010-2017.

Merid Mehari Woldemariam MW   Muluneh Atalay Goshu AG   Yenit Melaku Kindie MK   Kassa Getahun Molla GM  

PloS one 20201014 10


<h4>Background</h4>Drug-Resistant Tuberculosis (DR-TB) is a rising threat of the TB control program caused mainly by treatment interruption in Ethiopia. The success of the current treatment regimen for DR-TB is poor partly due to a high treatment interruption rate. Thus, this study assessed treatment interruption and associated factors among DR-TB patients.<h4>Methods</h4>An institution-based cross-sectional study was conducted among 550 DR-TB patients who have initiated treatment from September  ...[more]

Similar Datasets

| S-EPMC6469046 | biostudies-literature
| S-EPMC5558781 | biostudies-literature
| S-EPMC5065191 | biostudies-literature
| S-EPMC7059673 | biostudies-literature
| S-EPMC10209679 | biostudies-literature
| S-EPMC8654552 | biostudies-literature
| S-EPMC7734808 | biostudies-literature
| S-EPMC11350546 | biostudies-literature
| S-EPMC9215094 | biostudies-literature
| S-EPMC6072122 | biostudies-literature